Our integrated network‐based analysis has uncovered robust gene signatures that characterize the precision drug sensitivity of AML across a wide range of therapies, providing clinically relevant predictors of response to FLT3 Inhibitors. This evidence concerns the gene FLT3 and acute myeloid leukemia.